异源初免-加强型新型冠状病毒肺炎疫苗接种：初始反应原性数据 - Suppr

Suppr

超能文献

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.

作者信息

Shaw Robert H, Stuart Arabella, Greenland Melanie, Liu Xinxue, Nguyen Van-Tam Jonathan S, Snape Matthew D

机构信息

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford OX3 9DU, UK.

Division of Epidemiology and Public Health, School of Clinical Sciences, University of Nottingham, Nottingham, UK.

出版信息

Lancet. 2021 May 29;397(10289):2043-2046. doi: 10.1016/S0140-6736(21)01115-6. Epub 2021 May 12.

DOI:10.1016/S0140-6736(21)01115-6

PMID:33991480

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8115940/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45d5/8115940/9ef591dad470/gr1_lrg.jpg

相似文献

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.

Lancet. 2021 May 29;397(10289):2043-2046. doi: 10.1016/S0140-6736(21)01115-6. Epub 2021 May 12.

Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2.

Lancet Infect Dis. 2021 Sep;21(9):1212-1213. doi: 10.1016/S1473-3099(21)00420-5. Epub 2021 Jul 29.

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.

Lancet. 2022 Jan 1;399(10319):36-49. doi: 10.1016/S0140-6736(21)02718-5. Epub 2021 Dec 6.

Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.

EBioMedicine. 2022 Jan;75:103761. doi: 10.1016/j.ebiom.2021.103761. Epub 2021 Dec 17.

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination.

Nat Med. 2021 Sep;27(9):1530-1535. doi: 10.1038/s41591-021-01464-w. Epub 2021 Jul 26.

Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose.

Lancet. 2022 Feb 12;399(10325):625-626. doi: 10.1016/S0140-6736(22)00090-3. Epub 2022 Jan 18.

COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants.

Nat Commun. 2021 Jun 28;12(1):3991. doi: 10.1038/s41467-021-24285-4.

To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination.

Expert Rev Vaccines. 2021 Oct;20(10):1211-1220. doi: 10.1080/14760584.2021.1971522. Epub 2021 Sep 1.

Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine.

Biomed Pharmacother. 2022 Mar;147:112650. doi: 10.1016/j.biopha.2022.112650. Epub 2022 Jan 19.

Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study.

Lancet Infect Dis. 2021 Nov;21(11):1539-1548. doi: 10.1016/S1473-3099(21)00330-3. Epub 2021 Jun 23.

引用本文的文献

Challenges to the Effectiveness and Immunogenicity of COVID-19 Vaccines: A Narrative Review with a Systematic Approach.

Vaccines (Basel). 2025 Jul 24;13(8):789. doi: 10.3390/vaccines13080789.

Kidney Involvement in SARS-CoV-2 Infection: Peritoneal Dialysis as the Preferred Modality.

Vaccines (Basel). 2025 Jul 2;13(7):723. doi: 10.3390/vaccines13070723.

Challenges and Innovations in Pharmacovigilance and Signal Management During the COVID-19 Pandemic: An Industry Perspective.

Vaccines (Basel). 2025 Apr 29;13(5):481. doi: 10.3390/vaccines13050481.

Mortality in severe serious adverse events following heterologous and homologous prime-boost vaccination strategies for SARS-CoV-2: A retrospective cohort study.

PLoS One. 2025 May 23;20(5):e0323736. doi: 10.1371/journal.pone.0323736. eCollection 2025.

Heterologous prime-boost Zika virus vaccination induces comprehensive humoral and cellular immunity in mouse models.

Front Immunol. 2025 Apr 25;16:1578427. doi: 10.3389/fimmu.2025.1578427. eCollection 2025.

Profile of Humoral Immunity and B Cell Pool in Infection with the SARS-CoV-2 Prototype Strain and AZD1222 (ChAdOx nCoV-19) Vaccination.

Vaccines (Basel). 2025 Jan 21;13(2):101. doi: 10.3390/vaccines13020101.

Evaluating the risk of SARS-CoV-2 reinfection with the Omicron or Delta variant in Wales, UK.

PLoS One. 2024 Sep 6;19(9):e0309645. doi: 10.1371/journal.pone.0309645. eCollection 2024.

Reactogenicity Differences between Adjuvanted, Protein-Based and Messenger Ribonucleic Acid (mRNA)-Based COVID-19 Vaccines.

Vaccines (Basel). 2024 Jul 19;12(7):802. doi: 10.3390/vaccines12070802.

COVID-19 in City Council Civil Servants, 1 March 2020-31 January 2023: Risk of Infection, Reinfection, Vaccine Effectiveness and the Impact of Heterologous Triple Vaccination.

Vaccines (Basel). 2024 Feb 28;12(3):254. doi: 10.3390/vaccines12030254.

SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines.

Hum Vaccin Immunother. 2024 Dec 31;20(1):2301632. doi: 10.1080/21645515.2023.2301632. Epub 2024 Jan 11.

本文引用的文献

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

Lancet. 2021 Dec 19;396(10267):1979-1993. doi: 10.1016/S0140-6736(20)32466-1. Epub 2020 Nov 19.

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.

Lancet. 2020 Aug 15;396(10249):467-478. doi: 10.1016/S0140-6736(20)31604-4. Epub 2020 Jul 20.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.

作者信息

Shaw Robert H, Stuart Arabella, Greenland Melanie, Liu Xinxue, Nguyen Van-Tam Jonathan S, Snape Matthew D

机构信息

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford OX3 9DU, UK.

Division of Epidemiology and Public Health, School of Clinical Sciences, University of Nottingham, Nottingham, UK.

出版信息

Lancet. 2021 May 29;397(10289):2043-2046. doi: 10.1016/S0140-6736(21)01115-6. Epub 2021 May 12.

DOI:10.1016/S0140-6736(21)01115-6

PMID:33991480

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8115940/

Abstract

摘要

相似文献

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.

Lancet. 2021 May 29;397(10289):2043-2046. doi: 10.1016/S0140-6736(21)01115-6. Epub 2021 May 12.

Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2.

Lancet Infect Dis. 2021 Sep;21(9):1212-1213. doi: 10.1016/S1473-3099(21)00420-5. Epub 2021 Jul 29.

Lancet. 2022 Jan 1;399(10319):36-49. doi: 10.1016/S0140-6736(21)02718-5. Epub 2021 Dec 6.

Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.

EBioMedicine. 2022 Jan;75:103761. doi: 10.1016/j.ebiom.2021.103761. Epub 2021 Dec 17.

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination.

Nat Med. 2021 Sep;27(9):1530-1535. doi: 10.1038/s41591-021-01464-w. Epub 2021 Jul 26.

Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose.

Lancet. 2022 Feb 12;399(10325):625-626. doi: 10.1016/S0140-6736(22)00090-3. Epub 2022 Jan 18.

COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants.

Nat Commun. 2021 Jun 28;12(1):3991. doi: 10.1038/s41467-021-24285-4.

To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination.

Expert Rev Vaccines. 2021 Oct;20(10):1211-1220. doi: 10.1080/14760584.2021.1971522. Epub 2021 Sep 1.

Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine.

Biomed Pharmacother. 2022 Mar;147:112650. doi: 10.1016/j.biopha.2022.112650. Epub 2022 Jan 19.

Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study.

Lancet Infect Dis. 2021 Nov;21(11):1539-1548. doi: 10.1016/S1473-3099(21)00330-3. Epub 2021 Jun 23.

引用本文的文献

Challenges to the Effectiveness and Immunogenicity of COVID-19 Vaccines: A Narrative Review with a Systematic Approach.

Vaccines (Basel). 2025 Jul 24;13(8):789. doi: 10.3390/vaccines13080789.

Kidney Involvement in SARS-CoV-2 Infection: Peritoneal Dialysis as the Preferred Modality.

Vaccines (Basel). 2025 Jul 2;13(7):723. doi: 10.3390/vaccines13070723.

Challenges and Innovations in Pharmacovigilance and Signal Management During the COVID-19 Pandemic: An Industry Perspective.

Vaccines (Basel). 2025 Apr 29;13(5):481. doi: 10.3390/vaccines13050481.

Mortality in severe serious adverse events following heterologous and homologous prime-boost vaccination strategies for SARS-CoV-2: A retrospective cohort study.

PLoS One. 2025 May 23;20(5):e0323736. doi: 10.1371/journal.pone.0323736. eCollection 2025.

Heterologous prime-boost Zika virus vaccination induces comprehensive humoral and cellular immunity in mouse models.

Front Immunol. 2025 Apr 25;16:1578427. doi: 10.3389/fimmu.2025.1578427. eCollection 2025.

Profile of Humoral Immunity and B Cell Pool in Infection with the SARS-CoV-2 Prototype Strain and AZD1222 (ChAdOx nCoV-19) Vaccination.

Vaccines (Basel). 2025 Jan 21;13(2):101. doi: 10.3390/vaccines13020101.

Evaluating the risk of SARS-CoV-2 reinfection with the Omicron or Delta variant in Wales, UK.

PLoS One. 2024 Sep 6;19(9):e0309645. doi: 10.1371/journal.pone.0309645. eCollection 2024.

Reactogenicity Differences between Adjuvanted, Protein-Based and Messenger Ribonucleic Acid (mRNA)-Based COVID-19 Vaccines.

Vaccines (Basel). 2024 Jul 19;12(7):802. doi: 10.3390/vaccines12070802.

COVID-19 in City Council Civil Servants, 1 March 2020-31 January 2023: Risk of Infection, Reinfection, Vaccine Effectiveness and the Impact of Heterologous Triple Vaccination.

Vaccines (Basel). 2024 Feb 28;12(3):254. doi: 10.3390/vaccines12030254.

SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines.

Hum Vaccin Immunother. 2024 Dec 31;20(1):2301632. doi: 10.1080/21645515.2023.2301632. Epub 2024 Jan 11.

本文引用的文献

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

Lancet. 2021 Dec 19;396(10267):1979-1993. doi: 10.1016/S0140-6736(20)32466-1. Epub 2020 Nov 19.

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.

Lancet. 2020 Aug 15;396(10249):467-478. doi: 10.1016/S0140-6736(20)31604-4. Epub 2020 Jul 20.